Science 37 Holdings, Inc. Sustainability Profile
Science 37 Holdings, Inc., often referred to simply as Science 37, is a pioneering leader in the clinical research industry, headquartered in the United States. Founded in 2014, the company has rapidly established itself as a key player in the decentralised clinical trial space, offering innovative solutions that enhance patient engagement and streamline trial processes. With a focus on transforming the way clinical trials are conducted, Science 37 provides a comprehensive suite of services, including telehealth, mobile nursing, and patient-centric technology. This unique approach allows for greater accessibility and efficiency, setting the company apart in a competitive market. Recognised for its significant contributions to advancing clinical research, Science 37 has achieved notable milestones, positioning itself as a trusted partner for pharmaceutical and biotechnology companies seeking to accelerate drug development while improving patient outcomes.
DitchCarbon Score
How does Science 37 Holdings, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Science 37 Holdings, Inc.'s score of 29 is higher than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Science 37 Holdings, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company is a current subsidiary of eMed, LLC, which may influence its climate-related performance metrics. Despite the lack of direct emissions data, Science 37 Holdings, Inc. has not outlined any specific reduction targets or climate pledges. The absence of commitments to initiatives such as the Science Based Targets initiative (SBTi) or other recognised climate frameworks suggests a need for further development in their sustainability strategy. As a participant in the healthcare and clinical research sector, the company operates within an industry increasingly focused on reducing carbon footprints and enhancing environmental responsibility. However, without concrete data or commitments, it remains unclear how Science 37 Holdings, Inc. plans to address its carbon emissions and climate impact moving forward.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Scope 1 | 11,100,000,000 | 00,000,000,000 | 0,000,000,000 | 00,000,000,000 | 0,000,000,000 |
| Scope 2 | 1,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 00,000,000.0 | 00,000,000.0 | 0,000,000.0 |
How Carbon Intensive is Science 37 Holdings, Inc.'s Industry?
How Carbon Intensive is Science 37 Holdings, Inc.'s Location?
Science 37 Holdings, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Science 37 Holdings, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
